Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

I think we’re already there. Case in point: there are seven drugs in human trials that target lung or and/or other cancers caused by an acquired genetic abnormality called the ALK rearrangement (Figure). Roche’s Alectinib is in Phase 3. Ariad, Tesaro, Pfizer and Ignyta all have agents in Phase 2. There are four more compounds soon to enter human testing. That’s a lot of drugs that all target the same cancer causing mechanism.

http://www.forbes.com/sites/matthewherper/2014/10/23/could-high-drug-prices-be-bad-for-innovation/?partner=yahootix